South Dakota is uniquely positioned to be the “sweet spot” for the biotechnology industry, according to SAB Biotherapeutics Chief Science Officer, Dr. Christoph L. Bausch. Bausch presented the results of an intensive research study on the state of biotech in South Dakota when he presented to the Downtown Sioux Falls Rotary on Monday, July 24 at the Holiday Inn City Centre.
Curious about the opportunities in biotech, Bausch conducted unique research, classifying each of the 66 South Dakota-based biotech companies into a growth phase and identified complementary companies to attract to the state to grow and support these businesses. With over 200 students currently studying in the biotech field in the core market, along with the new USD Discovery District, South Dakota is an attractive spot. And it’s great for the economy with biotech jobs typically paying 57% more than many other local professions.
As Chief Science Officer, Bausch is responsible for antibody and antigen production, quality control laboratories, research collaborations, grant funding and clinical studies at SAB Biotherapeutics.
Curious about the opportunities in biotech, Bausch conducted unique research, classifying each of the 66 South Dakota-based biotech companies into a growth phase and identified complementary companies to attract to the state to grow and support these businesses. With over 200 students currently studying in the biotech field in the core market, along with the new USD Discovery District, South Dakota is an attractive spot. And it’s great for the economy with biotech jobs typically paying 57% more than many other local professions.
As Chief Science Officer, Bausch is responsible for antibody and antigen production, quality control laboratories, research collaborations, grant funding and clinical studies at SAB Biotherapeutics.
SAB Biotherapeutics, Inc. (SAB), is a Sioux Falls-based biopharmaceutical company on the leading edge of innovation, developing and delivering natural technologies that have the potential to transform the prevention and treatment of diseases from Ebola to cancer, and diabetes to influenza. SAB’s first-of-its-kind therapeutic production platform holds the promise of treatment of rare conditions, long-term diseases and global pandemic threats.
Prior to SAB, Dr. Bausch served in several business development positions, most recently for $7B global biorefining leader, Poet, LLC, where he structured strategic partnerships, prospected and vetted new technologies, and streamlined research and development
Dr. Bausch received his Ph.D. in Microbiology at The Ohio State University; Columbus, Ohio, completed Post-Doctoral Training at the Stowers Institute for Medical Research, Kansas City, Missouri and earned an M.B.A. from St. Louis University, St. Louis, Missouri in addition to a B.A. in Biology from the University of Nebraska-Lincoln, Lincoln, Nebraska.
Prior to SAB, Dr. Bausch served in several business development positions, most recently for $7B global biorefining leader, Poet, LLC, where he structured strategic partnerships, prospected and vetted new technologies, and streamlined research and development
Dr. Bausch received his Ph.D. in Microbiology at The Ohio State University; Columbus, Ohio, completed Post-Doctoral Training at the Stowers Institute for Medical Research, Kansas City, Missouri and earned an M.B.A. from St. Louis University, St. Louis, Missouri in addition to a B.A. in Biology from the University of Nebraska-Lincoln, Lincoln, Nebraska.
Program Highlights July 24, 2017:
- is on the leading edge of innovation, developing and delivering natural technologies in medicine (genetics, personalized medicine), agriculture (crops, microbes), livestock (immunizations, treating diseases like cancer and polio).
- South Dakota has the potential to become a driving force in the biotech industry. Currently, there are 66 SF-based biotech companies. There are over 200 students currently studying in the biotech field.
- The new USD Discovery District plays a part in growing our economy with biotech jobs. These jobs typically pay 57% more than many other professions.
Next Week’s Program:
Miles Beacom, Stephanie Sandlin, Jeff Scherschligt—SD Hall of Fame: A Panel Discussion